Research programme: peginterferon beta - Bolder BioTechnology

Drug Profile

Research programme: peginterferon beta - Bolder BioTechnology

Alternative Names: BBT-032; PegIFN-beta - Bolder BioTechnology; PegIFN-β - Bolder Biotechnology; Peginterferon beta - Bolder Biotechnology

Latest Information Update: 10 Nov 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bolder BioTechnology
  • Class Interferons
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer; Multiple sclerosis

Most Recent Events

  • 03 Nov 2010 Bolder BioTechnology receives Qualifying Therapeutic Discovery Project grant from the US Department of Health and Human Services for BBT 032 development in Multiple Sclerosis and Cancer
  • 03 Nov 2010 Preclinical trials in Cancer in USA (Parenteral)
  • 31 Aug 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top